According to the latest report by IMARC Group, titled “Asia Pacific Hospital Acquired Disease Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the asia pacific hospital acquired disease testing market is currently witnessing strong growth. Looking forward, IMARC Group expects the market to witness robust growth during 2021-2026.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request Free Report Sample: https://www.imarcgroup.com/asia-pacific-hospital-acquired-disease-testing-market/requestsample
A hospital acquired disease, or nosocomial infection, refers to a localized or systemic condition that is developed in a hospital during a visit. These diseases are generally caused by the presence of pathogens such as viruses, fungal parasites, and bacteria in the hospital environment. They can be tested and diagnosed using microarrays, polymerase chain reaction (PCR), and solid-phase hybridization.
The Asia Pacific hospital acquired disease testing market is primarily driven by the increasing incidences of catheter-associated urinary tract infection and catheter-related bloodstream infection (CRBSI). Various hospitals are focusing on expanding the in-house testing capacity, along with increasing the surveillance and identification of cultures of colonized nosocomial organisms, to prevent the transmission of infections. In addition to this, the rise in the morbidity rates due to infections in the region is also propelling the growth of the market. Moreover, the increasing length of stay in hospitals due to hospital-acquired diseases, which incurs high healthcare expenditure, is significantly impacting the demand for hospital-acquired disease testing in the Asia Pacific region.
Asia Pacific Hospital Acquired Disease Testing Market 2021-2026 Competitive Analysis and Segmentation:
Competitive Landscape with Key Players:
The competitive landscape of the asia pacific hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Market Segmentation:
The report has segmented the asia pacific hospital acquired disease testing market on the basis of indication and country.
Breakup by Indication:
- UTI (Urinary Tract Infection)
- SSI (Surgical Site Infection)
- Pneumonia
- Bloodstream Infections
- MRSA (Methicillin-Resistant Staphylococcus Aureus)
- Others
Breakup by Country:
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/asia-pacific-hospital-acquired-disease-testing-market
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Industry Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800